https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Delayed versus immediate cord clamping in preterm infants https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33645 Wed 24 Nov 2021 15:51:52 AEDT ]]> Neuropsychiatric correlates of olfactory identification and traumatic brain injury in a sample of impulsive violent offenders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54408 Tue 27 Feb 2024 13:50:09 AEDT ]]> Pelvic floor functional outcomes after total abdominal vs total laparoscopic hysterectomy for endometrial cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34527 Thu 17 Feb 2022 09:27:02 AEDT ]]> Weight and weight control behaviors during long-term endometrial cancer survivorship: Results of the Laparoscopic Approach to Cancer of the Endometrium long-term follow-up study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49343 Thu 11 May 2023 15:52:18 AEST ]]> Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12335 Sat 24 Mar 2018 08:15:52 AEDT ]]> Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13278 2 twice daily for 14 of every 21 days; n = 107) or continuously (650 mg/m² twice daily for 21 of every 21 days; n = 107), or to classical CMF (oral cyclophosphamide 100 mg/m² days 1 to 14 with intravenous methotrexate 40 mg/m² and fluorouracil 600 mg/m² on days 1 and 8 every 28 days; n = 109). The primary end point was quality-adjusted progression-free survival (PFS); secondary end points included PFS, overall survival (OS), objective tumor response, and adverse events. Intermittent and continuous capecitabine were to be compared first and, if similar (P > .05), combined for definitive comparisons versus CMF. Results: Quality-adjusted PFS (P = .2), objective tumor response rate (20%; P = .8), and PFS (median, 6 months; hazard ratio [HR], 0.86; 95% CI, 0.67 to 1.10; P = .2) were similar in women assigned capecitabine versus CMF. OS was longer in women assigned capecitabine rather than CMF (median, 22 v 18 months; HR, 0.72; 95% CI, 0.55 to 0.94; P = .02). Febrile neutropenia, infection, stomatitis, and serious adverse events were more common with CMF; hand-foot syndrome was more common with capecitabine. Conclusion: Capecitabine improved OS by being similarly active, less toxic, and more tolerable than CMF. Capecitabine is a good first-line chemotherapy option for women with advanced breast cancer who are unsuited to more intensive regimens.]]> Sat 24 Mar 2018 08:15:16 AEDT ]]> Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11196 Sat 24 Mar 2018 08:13:35 AEDT ]]> Lower preoperative quality of life increases postoperative risk of adverse events in women with endometrial cancer: results from the LACE trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27255 Sat 24 Mar 2018 07:29:12 AEDT ]]> Self-reported traumatic brain injury in a sample of impulsive violent offenders: neuropsychiatric correlates and possible "dose effects" https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54828 Fri 15 Mar 2024 11:54:55 AEDT ]]> Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage i endometrial cancer: a randomized clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34127 Fri 03 Dec 2021 10:32:07 AEDT ]]>